| Literature DB >> 32314698 |
Melissa Barreto Falcão1, Luciano Pamplona de Góes Cavalcanti2, Nivaldo Menezes Filgueiras Filho3,4, Carlos Alexandre Antunes de Brito5,6,7.
Abstract
Hydroxychloroquine (HCQ) has been used for the treatment of novel coronavirus disease (COVID-19) cases. However, evidence of efficacy remains limited, and adverse events can be associated with its use. Here, we report a case of a patient with severe COVID-19 who, after being administered HCQ, exhibited a 10-fold increase in serum levels of transaminases, followed by a rapid decrease after HCQ was withdrawn. Considering the significantly increased use of HCQ during the COVID-19 pandemic, this case alerts us to the potential for HCQ to be associated with hepatotoxicity and the need to monitor liver function during HCQ therapy.Entities:
Mesh：
Substances：
Year: 2020 PMID： 32314698 PMCID： PMC7253107 DOI： 10.4269/ajtmh.20-0276
Source DB: PubMed Journal: Am J Trop Med Hyg ISSN： 0002-9637 Impact factor: 2.345